Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

CorMedix (CRMD) Deferred Taxes (2019 - 2025)

CorMedix (CRMD) has disclosed Deferred Taxes for 3 consecutive years, with $33.9 million as the latest value for Q4 2025.

Quarterly Deferred Taxes changed N/A to $33.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$25.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$25.8 million for FY2025, N/A changed from the prior year.
Deferred Taxes hit $33.9 million in Q4 2025 for CorMedix, up from -$59.7 million in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $33.9 million in Q4 2025 to a low of -$59.7 million in Q3 2025.